Last reviewed · How we verify
Humulin R U-500
At a glance
| Generic name | Humulin R U-500 |
|---|---|
| Sponsor | Portal Diabetes, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants (PHASE1)
- A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (PHASE1)
- Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (PHASE1)
- Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI) (PHASE1)
- AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study (PHASE1)
- A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes (PHASE1)
- Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects (PHASE1)
- Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humulin R U-500 CI brief — competitive landscape report
- Humulin R U-500 updates RSS · CI watch RSS
- Portal Diabetes, Inc. portfolio CI